Drug intelligence / Profile preview

piroxicam + paracetamol

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Zoxicam Plus is a combination pharmaceutical product developed by Zakfas Pharmaceutical, primarily used for its analgesic and anti-inflammatory properties. It combines piroxicam, a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, with paracetamol (acetaminophen), a non-opioid analgesic. Piroxicam acts by non-selectively inhibiting the cyclooxygenase enzymes COX-1 and COX-2, which are essential for the biosynthesis of prostaglandins involved in pain and inflammation. Paracetamol provides complementary pain relief and antipyretic effects, likely through the inhibition of prostaglandin synthesis in the central nervous system. Zoxicam Plus is indicated for the symptomatic treatment of painful inflammatory conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute musculoskeletal disorders.

Brand names
Zoxicam Plus
Other names
Piroxicam/Paracetamol
02

Targets

COX-3 (Prostaglandin-endoperoxide synthase 1 splice variant)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on piroxicam + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on piroxicam + paracetamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call